Accelrys, Inc. (ACCL)

OklaBoston (< 20) Submitted: 10/1/2009 4:16:26 AM : Start Price: $5.72 ACCL Score: -13.24

Little known small-cap that reported a positive earnings surprise last quarter.

deylux (< 20) Submitted: 8/20/2008 12:40:43 AM : Start Price: $5.17 ACCL Score: -10.28

Not looking too hot, gotta say RED

ResearchLover (72.36) Submitted: 5/1/2008 8:50:09 PM : Start Price: $5.56 ACCL Score: +11.63

Positives: Organic growth is likely once they get a foothold in some of the broader industries they are targeting (see their website). Programmers can redeploy code and build a platform of interlocking products. Fits with the idea of buying shovel makers to tap growth in mining industry, i.e. buying research support to leverage growth in research in general. But I do like other molecular modeling software and am not familiar with theirs. So, this is a buy for their future growth prospects, branching out to reach a broader market, probably by redeploying some of their code but in packages that address workflow in different industries. Also a technical buy at the moment.

I first encountered this company in primary researcher's work on modeling chemical reactions, which he was licensing or developing for ACCL. So, they seem to be able to tap into the wider scientific community to develop the science underlying what should be proprietary analytics/algorithms.

NetscribeNanoTch (66.64) Submitted: 2/5/2007 8:12:11 AM : Start Price: $6.15 ACCL Score: -2.88

Accelry’s (ACCL) engages in design, development, marketing and support of software and related services which is helpful in the discovery and development of new and improved products and processes in the pharmaceutical, biotechnology, chemical, petrochemical and materials industries. The company markets its products and services worldwide, principally through its direct sales force, augmented by the use of third-party distributors with prime customers being commercial, government and academic organizations.

The company has been incurring losses for the past six years except for the three months ended March 31, 2004. The company has the history of losses and future profitability is also uncertain, as it has recently reported losses for the three quarter of fiscal 2007 also.

Additionally the market for molecular modeling and simulation products in the pharmaceutical and biotechnology industries is expected to be challenging due to the maturity of the market, industry consolidation, reducing level of discovery research activity and increased competition. This adds to the concern of the company as the company has been primarily involved into the sales of molecular modeling and simulation software in these markets. Though, ACCL is diverting towards chemical, petrochemical and materials industries, it will take some time before the company creates a position in this markets.

The company has recently announced that it will close its research and development facility in Bangalore, India as the management thinks that Accelrys is better suited to concentrate its new science efforts within its Cambridge and San Diego centers. This is expected to adversely affect the performance of the company as this center contributed greatly to the acceleration of its modernization process. Looking at all these developments that are expected to hamper the company’s growth prospects, the stock is expected to follow the suite.

NoahCAPS (< 20) Submitted: 12/5/2006 5:36:48 PM : Start Price: $6.02 ACCL Score: +2.77

New software release significantly increases the Accelrys solution's value for drug development customers